Comparative Pharmacology
Head-to-head clinical analysis: GENCEPT 10 11 21 versus OVULEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENCEPT 10 11 21 versus OVULEN.
GENCEPT 10/11-21 vs OVULEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GENCEPT 10/11-21 is a combination contraceptive vaginal ring containing ethinyl estradiol and etonogestrel. Ethinyl estradiol is an estrogen that suppresses gonadotropin release, inhibiting ovulation. Etonogestrel is a progestin that thickens cervical mucus, inhibiting sperm penetration, and alters the endometrium.
Ovulen is a combination oral contraceptive containing ethynodiol diacetate (a progestin) and mestranol (an estrogen). It inhibits ovulation by suppressing gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary. It also increases cervical mucus viscosity and alters endometrial development, impeding sperm penetration and implantation.
One tablet (10 mg ethinyl estradiol and 11 mg gestodene on days 1-7, then placebo on days 8-21) orally once daily for 21 days, followed by 7 placebo days.
1 tablet (1 mg ethynodiol diacetate, 50 mcg mestranol) orally once daily for 21 days, followed by 7 days of placebo or no medication.
None Documented
None Documented
Terminal elimination half-life is 24-30 hours; allows once-daily dosing; steady-state achieved in 5-7 days
Ethinylestradiol: 10-20 hours (mean 17 hours); Dimethisterone: 10-15 hours. Clinical context: Steady state achieved after 3-5 days; elimination prolonged in hepatic impairment.
Renal (30-40% as unchanged drug and metabolites), biliary/fecal (50-60% as metabolites)
Renal: 50-60% as metabolites (glucuronide and sulfate conjugates), biliary/fecal: 40-50% (enterohepatic circulation).
Category C
Category C
Oral Contraceptive
Oral Contraceptive